Nanoform and Takeda Bet on Miniature Science

Nanoform and Takeda test nanoparticle delivery for biologics, with early in-vivo results due in 2025

7 Nov 2025

Nanoform and Takeda are joining forces on a pre-clinical study that could reshape how complex biologic drugs reach the body. Announced in August 2024, the collaboration explores whether shrinking drug particles to the nanoscale can make treatments more effective and easier for patients to take.

At the heart of the project is Nanoform’s signature “nanoforming” process, which reduces drug particle size to enhance solubility, stability, and absorption. The research will test whether this approach can turn today’s intravenous biologics into simpler forms, such as shorter injections or even inhalable therapies.

The work remains early stage and non-GMP, but first in-vivo data are expected in 2025. Those results could offer critical clues about how well these nanoparticles perform in biological systems.

“This collaboration is not about rushing to market,” said one analyst familiar with the project. “It’s about pushing scientific boundaries to improve how next generation biologics are delivered.”

By pairing Takeda’s expertise in biologics with Nanoform’s particle engineering, the two companies hope to generate foundational data that can guide future clinical and regulatory strategies. Biologic drugs, large and complex molecules that are notoriously tricky to deliver, have long challenged researchers seeking safer, more convenient treatment options.

Though commercial use remains a distant goal, the Nanoform-Takeda partnership reflects a growing push across the industry to rethink drug delivery from the ground up. If successful, their findings could open the door to biologics that are not only more potent but also far less burdensome for patients.